SMT201500174B - Derivati ossidati di triazolilpurine utili come li-ganti del recettore di adenosina a2a e loro utilizzo come medicinali - Google Patents

Derivati ossidati di triazolilpurine utili come li-ganti del recettore di adenosina a2a e loro utilizzo come medicinali

Info

Publication number
SMT201500174B
SMT201500174B SM201500174T SM201500174T SMT201500174B SM T201500174 B SMT201500174 B SM T201500174B SM 201500174 T SM201500174 T SM 201500174T SM 201500174 T SM201500174 T SM 201500174T SM T201500174 B SMT201500174 B SM T201500174B
Authority
SM
San Marino
Prior art keywords
triazolylpurins
adenosine
medicines
useful
receptor ligands
Prior art date
Application number
SM201500174T
Other languages
English (en)
Italian (it)
Inventor
Walter Cabri
Patrizia Minetti
Giovanni Piersanti
Giorgio Tarzia
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of SMT201500174B publication Critical patent/SMT201500174B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SM201500174T 2009-03-20 2015-07-20 Derivati ossidati di triazolilpurine utili come li-ganti del recettore di adenosina a2a e loro utilizzo come medicinali SMT201500174B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09155690 2009-03-20
PCT/EP2010/053554 WO2010106145A1 (en) 2009-03-20 2010-03-18 Oxidated derivatives of triazolypurines useful as ligands of the adenosine a2a receptor and their use as medicaments

Publications (1)

Publication Number Publication Date
SMT201500174B true SMT201500174B (it) 2015-10-30

Family

ID=40941572

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500174T SMT201500174B (it) 2009-03-20 2015-07-20 Derivati ossidati di triazolilpurine utili come li-ganti del recettore di adenosina a2a e loro utilizzo come medicinali

Country Status (14)

Country Link
US (2) US9133197B2 (ja)
EP (1) EP2408775B1 (ja)
JP (1) JP5648044B2 (ja)
AR (1) AR075894A1 (ja)
DK (1) DK2408775T3 (ja)
ES (1) ES2542555T3 (ja)
HR (1) HRP20150766T1 (ja)
HU (1) HUE025704T2 (ja)
PL (1) PL2408775T3 (ja)
PT (1) PT2408775E (ja)
SI (1) SI2408775T1 (ja)
SM (1) SMT201500174B (ja)
TW (1) TWI473809B (ja)
WO (1) WO2010106145A1 (ja)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49457A (fr) 2017-06-22 2020-04-29 Novartis Ag Molécules d'anticorps se liant à cd73 et leurs utilisations
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
SG11202002886PA (en) * 2017-09-28 2020-04-29 Cstone Pharmaceuticals Suzhou Co Ltd Fused ring derivative as a2a receptor inhibitor
KR20200089286A (ko) 2017-11-16 2020-07-24 노파르티스 아게 조합 요법
RU2020121458A (ru) 2017-11-30 2021-12-30 Новартис Аг Химерный антигенный рецептор, нацеливающийся на bcma, и его пути применения
IL301295A (en) 2018-03-14 2023-05-01 Surface Oncology Inc Antibodies that bind CD39 and uses thereof
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
CN112384531B (zh) 2018-06-01 2024-05-14 诺华股份有限公司 针对bcma的结合分子及其用途
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
JP2022514315A (ja) 2018-12-20 2022-02-10 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体を含む投与計画及び薬剤組み合わせ
JP7488826B2 (ja) 2019-02-15 2024-05-22 ノバルティス アーゲー 置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
JP7483732B2 (ja) 2019-02-15 2024-05-15 ノバルティス アーゲー ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
TW202124444A (zh) 2019-09-16 2021-07-01 美商表面腫瘤學公司 抗ｃｄ３９抗體組合物及方法
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
JP2022549854A (ja) 2019-09-25 2022-11-29 サーフィス オンコロジー インコーポレイテッド 抗ｉｌ－２７抗体及びその使用
CA3165399A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
US20230321067A1 (en) 2020-06-23 2023-10-12 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP2023536164A (ja) 2020-08-03 2023-08-23 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
IL302569A (en) 2020-11-06 2023-07-01 Novartis Ag CD19 binding molecules and their uses
EP4284510A1 (en) 2021-01-29 2023-12-06 Novartis AG Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3990061B2 (ja) * 1998-01-05 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 プリン誘導体および糖尿病の予防・治療剤としてのアデノシンａ２受容体拮抗剤
CA2315736A1 (en) 1998-01-05 1999-07-15 Eisai Co., Ltd. Purine compounds and adenosine a2 receptor antagonist as preventive or therapeutic for diabetes mellitus
KR100694684B1 (ko) * 1999-07-02 2007-03-13 에자이 알앤드디 매니지먼트 가부시키가이샤 축합 이미다졸 화합물 및 당뇨병 치료약
JP2004502640A (ja) * 2000-02-10 2004-01-29 ニューヨーク・ユニバーシティ 肝繊維症、硬変症および脂肪肝を治療および予防するアデノシンａ２ａ受容体拮抗薬
US6770651B2 (en) * 2001-06-29 2004-08-03 Venkata Palle A2B adenosine receptor antagonists
ITRM20010465A1 (it) 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam
JPWO2003020723A1 (ja) * 2001-08-30 2004-12-16 協和醗酵工業株式会社 ［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
WO2006129626A1 (ja) * 2005-05-30 2006-12-07 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]トリアゾロ[1,5-c]ピリミジン誘導体の製造法

Also Published As

Publication number Publication date
US20160002244A1 (en) 2016-01-07
EP2408775A1 (en) 2012-01-25
TW201100425A (en) 2011-01-01
US9133197B2 (en) 2015-09-15
JP2012520854A (ja) 2012-09-10
US20120053191A1 (en) 2012-03-01
HUE025704T2 (en) 2016-04-28
EP2408775B1 (en) 2015-06-17
ES2542555T3 (es) 2015-08-06
JP5648044B2 (ja) 2015-01-07
SI2408775T1 (sl) 2015-08-31
DK2408775T3 (en) 2015-07-27
PT2408775E (pt) 2015-08-05
WO2010106145A1 (en) 2010-09-23
HRP20150766T1 (hr) 2015-08-14
AR075894A1 (es) 2011-05-04
PL2408775T3 (pl) 2015-10-30
TWI473809B (zh) 2015-02-21

Similar Documents

Publication Publication Date Title
SMT201500174B (it) Derivati ossidati di triazolilpurine utili come li-ganti del recettore di adenosina a2a e loro utilizzo come medicinali
SMT201500097B (it) Derivati di 4-amminopirimidina e loro uso come antagonsiti del recettore di adenosina a2a
CY2023012I1 (el) Παραγωγα κινολιν-8-σουλφοναμιδιου εχοντα αντικαρκινικη δραση
SMT201600198B (it) Derivati di 1,2,4-triazina-4-ammina
SMT201500036B (it) Derivati di cromenone con attivita' antitumorale
SMT201600099B (it) Derivati citotossici di benzodiazepine
SMT201600225B (it) DERIVATI DI 1,2,4-TIAZOLlDIN-3-0NE E LORO USO NEL TRATTAMENTO DEL CANCRO
DK2192109T3 (da) BICYKLISKE y-AMINOSYREDERIVATER
SMT201600338B (it) Formulazioni farmaceutiche comprendenti derivati di1-(beta-d- glucopiranosil)- 2-tienilmetilbenzene come inibitori di sglt
DK2511282T3 (da) Uracylspirooxetannukleosider
SMT201600076B (it) Derivati di 2-osso-1-pirrolidinil imidazotiadiazolo
SMT201300067B (it) Applicazioni terapeutiche di derivati di chinazolindione
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
FI20085767A0 (fi) Kipsituote
SMT201400080B (it) Derivati di pirazinoossazepina
SMT201600262B (it) Derivati benzazolici come ligandi del recettore h4 dell'istamina
SMT201600405B (it) Derivati di arilalchilamminocarbossammide fluorurati
SMT201500113B (it) Processp per preparare derivati di alfa-carbossammide
SMT201400157B (it) Derivati di 2-piridin-2-il-pirazol-3(2H)-one, loropreparazione e loro uso terapeutico
SMT201500182B (it) Nuovi derivati di 8-idrossichinoline-7-carbossammidi terziarie e loro usi
FR2937549B1 (fr) Nanoparticules de derives beta-lactamine
DK2380892T3 (da) Imidazothiazolderivat med prolinringstruktur
SMT201500067B (it) Derivati di acilbenzene
FR2953410B1 (fr) Compositions antivirales pharmaceutiques ou veterinaires
BRPI1008019A2 (pt) derivados de 6-(6-substituido-triazolo piridazina-sufanil) 5-flúor-benzo-tiazóis e 5-flúor-benzimidazóis: preparo, aplicação como medicamentos e utilização como inibidores de met